Preliminary study results confirm that the drug resmetirom reduces the presence of fat, inflammation, cell damage and fibrosis in the liver.
Read moreLa FDA ha aprobado Duvyzat (givinostat), un medicamento oral, para el tratamiento de la Distrofia Muscular de Duchenne (DMD) en pacientes de 6 años o más.
Read moreThis project, coordinated by Asebio, brings together ZeClinics' target validation and in vivo drug screening capabilities, Celtarys Research's scientific knowledge in fluorescent tool design and synth...
Read moreOryzon Genomics, S.A. announces that it has obtained the INNOVATIVE SME seal from the Spanish Ministry of Science and Innovation, and has consequently been registered in the Public Registry of INNOVAT...
Read moreEl resultado de un estudio pionero avala la seguridad de los bioimplantes llamados PeriCord, hechos de células madre de cordón umbilical y pericardio de un donante de tejidos que hace que la zona af...
Read moreOncoheroes Biosciences reveals the development of an innovative screening platform aimed at identifying potential drug candidates for medulloblastoma, a type of brain cancer prevalent in children
Read moreOryzon Genomics announced today that the U.S. Food and Drug Administration (FDA) has approved the Investigational New Drug (IND) application to initiate a Phase I/II trial with iadademstat plus immune...
Read moreThe use of artificial intelligence (AI) in healthcare has significantly revolutionized the industry. With its ability to process vast amounts of data, AI has the potential to transform patient care by...
Read moreSOM Biotech, a clinical-stage drug discovery and development company based on a unique proprietary Artificial Intelligence platform (SOMAIPRO®), is pleased to announce that the recruitment of the Pha...
Read moreAs Oncoheroes prepares to evaluate the efficacy of its lead compound, volasertib, across five pediatric cancer indications, including rhabdomyosarcoma, the Super Sam Foundation once again steps forwar...
Read moreDescriben RMC-7977, un compuesto preclínico con un perfil inhibidor multiselectivo de RAS(ON), que fue diseñado para inhibir el espectro completo de mutaciones oncogénicas de RAS, incluyendo mutaci...
Read moreThis article explores the rise of biotech collaborations in pharma, the impact of M&A on the industry, the role of technology in biotech advancements, the regulatory challenges faced by pharma in its ...
Read more